| Literature DB >> 28952492 |
Vaibhav Murthy1, Robert K Delong2.
Abstract
RNA nanotechnology is attracting a great deal of attention recently. As the multiple roles that RNA plays in molecular biology and physiological regulation become clearer, there are many opportunities for engineering RNA-Nanoparticle Complexes (RNA-NPCs). The high "engineerability" of RNA-NPCs comes from the ability to modify the RNA and NP chemistry. For example, the NP can be derived from materials with anticancer activity and the RNA delivered by it, designed to target cell signaling pathways that contribute to the molecular basis of these diseases. Despite this rapid advancement and the availability of new quantification and characterization techniques, a key challenge is to develop a better understanding of the RNA-nanobio interface; that is, the interactions of RNA with NP (RNA-nanobio interface) and how that impacts the structure, function, delivery, and activity of the RNA. Here, we attempt to summarize the state-of-the-art in this new and exciting field, and to lay out potential directions for bioengineering research on RNA-NPCs.Entities:
Keywords: RNA-nanobio interface; RNA-nanoparticle complexes; nano-bio interface
Year: 2017 PMID: 28952492 PMCID: PMC5590433 DOI: 10.3390/bioengineering4010013
Source DB: PubMed Journal: Bioengineering (Basel) ISSN: 2306-5354
Figure 1Literature search on the number of RNA-NP manuscripts published (on PubMed) using the keyword “RNA Nanoparticle” (or “RNA-NP”, “RNA-Nanoparticle” variations). The number of actual articles with RNA-NP content is substantially lower than the number from the general published (of RNA-NP) article search.
Figure 2Some examples of RNA chemical modifications which can now be synthesized due to the availability of various synthons compatible with automated nucleic acid synthesizers. (A) Modifications in the phosphodiester backbone such as phosphorothioate (S=P)-or-boranophosphate (BH2-P); (B) Modifications (most commonly at 5′ and 3′) with fluorescence dyes (5′-Fluorescein or 6-FAM in figure) allow for visual detection of RNA-NPCs (RNA-Nanoparticle Complexes), since RNA does not possess intrinsic fluorescence; (C) Modifications in the ribose such as in the 2′ position (O-Me, -F and others or ring modified versions).
Figure 3Examples of NP (Nanoparticle) modifications. (A) Cell-penetrating peptide-decorated NPs enhance cellular uptake of the NP (B) Polymer modifications such as PEG (polyethyleneglycol) (in figure) and PEI (polyethyleneimine) enhance NP stability by preventing aggregation in solution; (C) Amino Acid modifications such as arginine or lysine improve RNA binding to NP. Certain aptamers are synthesized with specific amino acid recognition motifs; (D) Surfactant capping modifications such as citrate, CTAB (cetyltrimethylammonium bromide) etc., have been used to restrict NP size, prevent aggregation, and improve stability in solution.
Characterizing the RNA-Nanobio interface.
| RNA+ Modification | NP+ Modification | RNA-Nanobio Characterization | Biological Significance | Ref. | |
|---|---|---|---|---|---|
| Anti-Sense | - | 1H NMR, FT-IR, Z-potential (ζ) | Selectively target CD33 positive Kasumi-1 cells | [ | |
| 2′-O-Met, FAM | AFM (Atomic Force Microscopy) | Increased cellular uptake by primary lung cancer cells and fibroblasts. | [ | ||
| PNA | SEM, TEM, FT-IR, Z-potential, MALDI-TOF MS 2, UV Abs. | Higher cellular uptake | [ | ||
| TcDNA + PS And B-PPMO | TEM, DLS (Dynamic Light Scatter), Critical Micelle Concentration (CMC), Z-potential | ASOs had increased inclination to self-assemble into nanoparticles | [ | ||
| Aptamer | Apt1 (anti-CD44)+ 2′-F | Z-potential, Gel electrophoresis | Enhanced CD44 binding | [ | |
| anti-PSMA 4 | Z-potential, SEM | PMSA specific | [ | ||
| anti-PSMA A9 | DLS, Fluorescence | Selectively labels | [ | ||
| Endo28 5 Aptamer | Serum Stability with polyacrylamide gel, Z-potential, DLS | RNA-NP showed increased binding to AnnexinA2 expressing cancer cells-IGROV-1 | [ | ||
| microRNA | miR-122 mimic | Z-potential | Preferentially taken up by tumor cell lines | [ | |
| Anti-miR-155 PMO and PNA | BCA Assay 6, | Inhibition of miRNA | [ | ||
| miR-145 | Z-potential, UV spectrophotometry | Overexpression of ectopic miR-145 in PC3 and MCF7 cell types. | [ | ||
| Anti-miR-21 | Z-potential, hydrodynamic diameter, Temperature Gradient Gel Electrophoresis (TGGE) | Specific delivery of anti-miR-21 to LNCaP-FGC (PMSA+) cells | [ | ||
| Ribozymes | Rzs | DLS, TEM, EtBr Displacement Assay 5, 1H NMR, Electrophoretic Mobility Shift | Stable complexes formed | [ | |
| MGMT 7+ Fluorescein+ 5′Cy5 | Gel elec, RT-PCR, | Cleaved MGMT substrate | [ | ||
| siRNA | Notch1-homo-siRNA-FAM | Z-potential, TEM, Gel electrophoresis | Protect against RNase A in serum | [ | |
| anti-survivin siRNA | FT-IR, Z-potential, | Increased cell uptake | [ | ||
| VEGF siRNA/ B-cell lymphoma siRNA | Gel retardation assay, DLS, Z-potential | Delivered specifically to integrin-overexpressing cells | [ | ||
| FASE siRNA+ Bcl-xl/2 strand 8+ Cy3 | UV-visible melting, UV-visible spectrophotometry for stability, DLS, | Controlled release of siRNA | [ | ||
1 DOC-PEI conjugate was formulated and incorporated into the liposome to facilitate endosomal release of ASO; 2 Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry; 3 Both these have been shown to have high CD44 expression ; 4 Prostate Specific Membrane Antigen 5 Measures surface density of NP with modifications; 6 Used to determine the stability of NPs formed. Depending on the weight ratio of NP: Rzs- low weight ratio, there is only slight exclusion of EtBr showing low complexation of NP-RNA; 7 O6-methylguanine-DNA methyltransferase (MGMT); 8 Fatty Acid Synthase siRNA was flanked by DNA spacers and Bcl-xl/2 RNA sequences were added as recognition sequences.
Figure 4Protein Corona agglomeration causes changes in the identity of the RNA-NPC therapeutic. Interactions with proteins can cause masking of the RNA of interest, rendering the RNA-NPC ineffective.